Is there any association between plasma lipid profile and severity of COVID-19?

COVID-19 Cholesterol, LDL Humans Lipoproteins Prospective Studies SARS-CoV-2
Atorvastatin COVID-19 HDL-cholesterol LDL-cholesterol Statins

Journal

Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592

Informations de publication

Date de publication:
06 2022
Historique:
received: 18 10 2021
revised: 20 04 2022
accepted: 25 04 2022
entrez: 27 5 2022
pubmed: 28 5 2022
medline: 1 6 2022
Statut: ppublish

Résumé

COVID-19 is an infectious disease which caused a pandemic with many diseases and fatalities. This new variant of coronavirus called SARS-CoV-2 and is primarily characterized by respiratory symptoms. There are some data indicating that LDL-cholesterol (LDL-C) as well as HDL-cholesterol (HDL-C) levels are inversely correlated to disease severity and could act as a predictor for disease progression and unfavorable prognosis. However, the results of some other studies do not confirm this. This current study aimed to provide an answer to this question. This prospective, single-center study analyzed 367 confirmed COVID-19 patients to find whether there are any differences in plasma lipoproteins between survivors and non-survivors patients or between the patients with a "duration of ≤10 days intensive unit care (ICU) stay" and patients with a "duration of >10 days ICU stay". No association between any lipid/lipoprotein parameter and the severity of COVID-19 could be found but survivors and non-survivors did differ concerning total cholesterol and LDL-C levels. Multivariate cox regression analysis could not prove any association between lipids/lipoproteins and severe events in COVID-19 patients. Significantly less non-survivors with COVID-19 were taking atorvastatin than survivors which is consistent with the majority of previous findings.

Sections du résumé

BACKGROUND
COVID-19 is an infectious disease which caused a pandemic with many diseases and fatalities. This new variant of coronavirus called SARS-CoV-2 and is primarily characterized by respiratory symptoms. There are some data indicating that LDL-cholesterol (LDL-C) as well as HDL-cholesterol (HDL-C) levels are inversely correlated to disease severity and could act as a predictor for disease progression and unfavorable prognosis. However, the results of some other studies do not confirm this. This current study aimed to provide an answer to this question.
METHODS
This prospective, single-center study analyzed 367 confirmed COVID-19 patients to find whether there are any differences in plasma lipoproteins between survivors and non-survivors patients or between the patients with a "duration of ≤10 days intensive unit care (ICU) stay" and patients with a "duration of >10 days ICU stay".
RESULTS
No association between any lipid/lipoprotein parameter and the severity of COVID-19 could be found but survivors and non-survivors did differ concerning total cholesterol and LDL-C levels.
CONCLUSION
Multivariate cox regression analysis could not prove any association between lipids/lipoproteins and severe events in COVID-19 patients. Significantly less non-survivors with COVID-19 were taking atorvastatin than survivors which is consistent with the majority of previous findings.

Identifiants

DOI: 10.1016/j.clnesp.2022.04.026 PMID: 35623812 PMC: PMC9047402
pubmed: 35623812
pii: S2405-4577(22)00252-2
doi: 10.1016/j.clnesp.2022.04.026
pmc: PMC9047402
pii:
doi:

Substances chimiques

Cholesterol, LDL 0
Lipoproteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-196

Informations de copyright

Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Références

PLoS One. 2020 Sep 24;15(9):e0239573
pubmed: 32970772
Lipids. 2011 Apr;46(4):333-40
pubmed: 21207250
Thromb Haemost. 2015 Aug 31;114(3):546-57
pubmed: 26017749
Arch Med Sci. 2019 Nov 12;17(5):1423-1428
pubmed: 34522273
Front Med (Lausanne). 2021 Feb 03;8:639804
pubmed: 33614688
Lipids Health Dis. 2020 Sep 7;19(1):204
pubmed: 32892746
BMJ Open. 2020 Dec 4;10(12):e044421
pubmed: 33277291
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Adv Clin Exp Med. 2021 Feb;30(2):153-156
pubmed: 33571404
Arch Med Sci. 2020 Nov 02;16(6):1432-1439
pubmed: 33224343
J Pers Med. 2021 Feb 10;11(2):
pubmed: 33578937
Cardiorenal Med. 2020;10(2):69-84
pubmed: 32062648
Nat Rev Cardiol. 2013 Aug;10(8):453-64
pubmed: 23736519
Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):157-164
pubmed: 33135047
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Clin Nutr ESPEN. 2021 Aug;44:437-444
pubmed: 34330502
J Clin Lipidol. 2020 May - Jun;14(3):297-304
pubmed: 32430154
Am J Med Sci. 2021 Jun;361(6):725-730
pubmed: 33667433
Respiration. 1993;60(3):178-81
pubmed: 8210722
Am J Physiol Renal Physiol. 2006 Jun;290(6):F1376-81
pubmed: 16449359
Arch Med Sci. 2020 Apr 25;16(3):490-496
pubmed: 32399094
Arch Med Sci. 2021 Feb 10;17(3):579-595
pubmed: 34025827
Pharmacol Rep. 2021 Jun;73(3):769-780
pubmed: 33608850
BMC Med. 2017 Aug 1;15(1):144
pubmed: 28760142
Biomed Res Int. 2021 Sep 23;2021:1901772
pubmed: 34568488
Angiology. 2021 Feb;72(2):122-130
pubmed: 32864982
Front Med (Lausanne). 2021 May 04;8:592336
pubmed: 34017839
Rev Med Virol. 2019 Sep;29(5):e2056
pubmed: 31172625
Sci Rep. 2021 Mar 30;11(1):7217
pubmed: 33785815
Heart Fail Rev. 2021 Sep;26(5):1259-1272
pubmed: 32008148
Curr Opin Clin Nutr Metab Care. 2016 Mar;19(2):111-5
pubmed: 26828580
Arch Med Sci. 2021 Aug 09;17(5):1414-1417
pubmed: 34522271
Hypertension. 2013 Feb;61(2):400-7
pubmed: 23297374
Nat Rev Cardiol. 2021 Mar;18(3):194-209
pubmed: 33214651
Prog Lipid Res. 2015 Oct;60:50-73
pubmed: 26416579
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Clin Lab. 2019 Dec 1;65(12):
pubmed: 31850701
Food Sci Nutr. 2020 Oct 27;8(11):6144-6152
pubmed: 33282265
Clin Chim Acta. 2020 Nov;510:105-110
pubmed: 32653486
J Infect Dis. 2010 Jan 15;201(2):285-92
pubmed: 19954384
Pharmacol Res. 2018 Sep;135:230-238
pubmed: 30120976
Clin Chim Acta. 2021 Jun;517:66-73
pubmed: 33639119
Nat Commun. 2021 Feb 26;12(1):1325
pubmed: 33637713

Auteurs

Farshid Rahimibashar (F)

Department of Anesthesiology and Critical Care, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Ladan Sedighi (L)

Department of Medical and Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Alireza Shahriary (A)

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Zeljko Reiner (Z)

Department of Internal Diseases, University Hospital Center Zagreb School of Medicine, Zagreb University, Zagreb, Croatia.

Mohamad Amin Pourhoseingholi (MA)

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Golshan Mirmomeni (G)

Hearing Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Ali Fathi Jouzdani (AF)

Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.

Amir Vahedian-Azimi (A)

Trauma Research Center, Nursing Faculty, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: amirvahedian63@gmail.com.

Tannaz Jamialahmadi (T)

Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Amirhossein Sahebkar (A)

Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sahebkara@mums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Is there any association between plasma lipid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Lipoprotéines LDL › Cholestérol LDL › Is there any association between plasma lipid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Is there any association between plasma lipid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Is there any association between plasma lipid...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Is there any association between plasma lipid...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Is there any association between plasma lipid...